Denmark's Novo Nordisk on Monday said it has agreed to buy Cardior Pharmaceuticals for up to 1.03 billion euros ($1.11 billion) to strengthen its...
COPENHAGEN - Denmark's Novo Nordisk on Monday said it has agreed to buy Cardior Pharmaceuticals for up to 1.03 billion euros to strengthen its cardiovascular pipeline.
The deal includes Cardior's lead compound CDR132L, currently in phase 2 clinical development for the treatment of heart failure, Novo said.The transaction price includes an upfront payment and additional payments if certain development and commercial milestones are achieved, the company said, adding it would fund the acquisition from financial reserves.
King 'frustrated' about speed of cancer recovery and is 'pushing' staff to be able to return to duties, says Peter Phillips Many of us want to eat healthier, but it's tough with so many different health claims out there. Nutritionists and dietitians are here to help you see past the buzzwords.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly and Novo Nordisk's Diabetes Drugs Being Studied for Other Health BenefitsEli Lilly's Mounjaro and Novo Nordisk's Ozempic and Wegovy are being investigated for potential health benefits beyond diabetes treatment. A study is examining whether Novo's Wegovy can reduce alcohol intake in patients with early Alzheimer's disease. Another study is testing Novo's semaglutide in combination with clot removal therapy for stroke patients. Lilly is also conducting research on the effects of their drugs on Alzheimer's disease and obesity.
Read more »
Parents Push Back Against Making Rhode Island A Sanctuary State for Childhood Trans Surgeries And PharmaceuticalsNicole Solas , Bob Chiaradio, Ramona Bessinger, and others testify in RI Senate hearing against the “Healthcare Provider Shield Act” which would insulate Rhode Island doctors and their patients from civil and criminal complaints filed in other states.
Read more »
AstraZeneca buys Hamilton-based smart cancer drug maker Fusion Pharmaceuticals for $2-billionDeal will be ‘good for Canada’ as buyer will keep and expand local manufacturing presence, former Fusion chairman says
Read more »
AstraZeneca to buy Canadian cancer treatment developer Fusion PharmaceuticalsHAMILTON — Canadian cancer treatment developer Fusion Pharmaceuticals Inc. has signed a deal to be bought by AstraZeneca in an agreement valued at up to US...
Read more »
AstraZeneca to buy Canadian cancer treatment developer Fusion PharmaceuticalsHAMILTON — Canadian cancer treatment developer Fusion Pharmaceuticals Inc. has signed a deal to be bought by AstraZeneca in an agreement valued at up to US$2.4 billion.
Read more »
AstraZeneca acquires Fusion Pharmaceuticals in $2B dealAstraZeneca (AZN) has announced its acquisition of Fusion Pharmaceuticals (FUSN), a Canadian drug developer, in an all-cash deal valued at $2 billion. This...
Read more »